Study to Determine the Significant Prognostic Factors Related with Better Clinical Outcome in Glioblastoma Multiforme Patients

Abstract

Aim: In adults glioblastoma multiforme (GBM) is the deadly and utmost communal brain tumor. GBM has poor prognosis and the median general endurance hardly surpasses one-year. In this study, we retrospectively assessed the demographic and clinical characteristics of patients with GBM and to recognize significant prognostic factors that may be associated with better results in our population. Material and Methods: The clinicopathological, treatment parameters (ie, chemotherapy, radiotherapy and the surgical resection extent) and demographic parameters were attained from medical records. SPSS version 23.0 was applied for all statistical analyzes. The overall survival and median progression-free survival was 14.1 and 10 months; correspondingly. Results: In the subjects with the longest overall survival group, a tumor was found in the frontotemporal area, and then in the frontal area. In a univariate analysis, age, co-administration of adjuvant temozolomide (TMZ) and chemoradiotherapy were prognosticators of both overall survival (OS) and progression-free survival (PFS). Though, in multivariate analysis, radiotherapy and age were important determinants of endurance. Subjects who received the cyber-knife after relapse had a lengthier operating system. Conclusion: The patients were retrospectively assessed with GBM in the facility, and the outcomes confirmed formerly testified factors influencing GBM endurance.